Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxaceprol is a small molecule anti-inflammatory drug used primarily for the treatment of osteoarthritis and other degenerative or inflammatory joint disorders, including rheumatoid arthritis and inflammation of connective tissues[1][3][4][5]. It is a derivative of the amino acid proline[2]. Oxaceprol acts by inhibiting the accumulation, adhesion, and migration of leukocytes (white blood cells), particularly neutrophils, into inflamed joints or tissues. This mechanism reduces pain, swelling, stiffness, and other symptoms associated with joint inflammation without significantly inhibiting prostaglandin synthesis—a key difference from traditional NSAIDs[1][6]. Oxaceprol has been shown to be well-tolerated with fewer gastrointestinal side effects compared to conventional NSAIDs. It is available in oral formulations such as tablets or capsules and has been widely used in Europe for over 30 years[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxaceprol.